Ireland Pushes for Faster Access to Rare Disease Drug Amid Bureaucratic Hurdles

Irish Taoiseach Micheál Martin has expressed a strong desire for patients suffering from Friedreich's Ataxia to gain access to the first available treatment for the condition as swiftly as possible. His comments came in response to Sinn Féin leader Mary Lou McDonald's inquiry in the Dáil regarding the absence of the drug Skyclarys from the upcoming HSE Drugs Group agenda.

“

patients living with Friedreich's Ataxia in Ireland have access to the first treatment for the condition "as fast as we possibly can".

Ms. McDonald criticized the delay as "intolerable and cruel," emphasizing that the disease does not pause and that every lost day has significant consequences. She highlighted the presence of protesting patients outside Leinster House and in the public gallery, urging a commitment to provide them with access to the treatment. Taoiseach Martin assured that the government is working to get the drug approved, stating, "We need to get this decided upon as quickly as we possibly can."

While the drug will not be discussed at tomorrow's meeting, the government aims to have it on the agenda for the July meeting. Independent Ireland TD Michael Collins also called for the Taoiseach's intervention, noting his repeated attempts to address the issue with the Minister for Health and expressing frustration at being "left in limbo."

“

Further delay is intolerable and cruel because there is no pause in this disease. "Every day lost has consequences."

Martin described Friedreich's Ataxia as a "cruel" and "relentlessly progressive disease." He pointed out that the drug is approved in other European countries, but Irish patients are again left waiting due to what he termed "bureaucracy," causing their "time and their health slips away."

“

We need to get this decided upon as quickly as we possibly can. "There are many, many families out there worried and stressed,"

Following a meeting with Craig Coady, whose son Paudie has Friedreich's Ataxia and whose younger son Rory recently died from the disease, Martin was described as "emotional" and "sympathetic." Emily Felix, a 28-year-old trainee solicitor with the condition, stressed the urgency, stating, "For them, it's only an administrative delay, for me that will be permanent loss that I can never regain." The HSE maintains that reimbursement decisions are based on "objective, scientific and economic grounds."

“

But here we are again, left in limbo.